Neostem Inc. set its sights on the hot cancer immunotherapy market with an agreement to acquire California Stem Cell Inc. (CSC) through a stock transaction. The New York-based cell therapy company, whose most advanced program, AMR-001, is a chemotactic hematopoetic stem cell product to treat damaged heart muscle following heart attack, moves melapuldencel-T, an autologous stem cell immune-based therapy, to the head of the class and takes on the challenge of a phase III trial with the CSC buy.